Using caspofungin to treat Pneumocystis pneumonia in people with HIV.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the efficacy of caspofungin, an echinocandin, in treating Pneumocystis jirovecii pneumonia (PCP) in patients with HIV/AIDS. Given the safety concerns associated with the standard treatment, trimethoprim/sulfamethoxazole, this research aims to explore caspofungin's potential as a safer alternative. The study will include patients diagnosed with probable or proven PCP and will assess their clinical outcomes and safety profiles. The findings could provide valuable insights into the effectiveness of caspofungin in this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section).
* Have clinical laboratory and virological diagnostic laboratory studies at the time of admission.

  * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.:

Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism.

Exclusion Criteria:

* With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).
* Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.

Where it's running

• Center for Research in Infectious Diseases (CIENI)
  Mexico City, Tlalpan, Mexico Recruiting

Study contacts

• Principal investigator: Santiago Avila, PhD — Center for Research in Infectious Diseases (CIENI)
• Study coordinator: Xavier Flores, MD
• Email: xavier.flores@cieni.org.mx
• Phone: (+52 55) 5940 2110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap

  This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.

  Recruiting at 10 sites Phase 4 CAN Community Health · Clearwater, Florida and 9 other locations · NCT07476339

• Weekly long-acting HIV-1 meds switch for people with undetectable virus

  This study tests whether switching to weekly oral long-acting HIV medicines works as well as staying on current daily pills for people with HIV who already have an undetectable viral load.

  Recruiting at 2 sites Phase 2 Gilead Sciences · Ft. Pierce, Florida and 1 other locations · NCT07841990

• HIV in Hong Kong: patterns, transmission, and burden over time

  This project tests how HIV-1 infections in Hong Kong have changed over several years by following newly diagnosed adults and analyzing their subtypes, transmission links, and community burden.

  Recruiting Chinese University of Hong Kong · North Point · NCT07725042

• GS-0415 safety and PK in people with HIV on ART

  This study tests GS-0415 in adults with HIV who are on stable ART to see if it is safe, tolerable, and how the drug behaves in the body.

  Recruiting at 15 sites Phase 1 Gilead Sciences · Los Angeles, California and 15 other locations · NCT07719491

• Gilead study of GS-3242 with Lenacapavir for people starting HIV treatment compared with Biktarvy

  This study tests whether injecting GS-3242 with Lenacapavir can work as well as Biktarvy for people newly starting HIV treatment.

  Recruiting at 19 sites Phase 2/3 Gilead Sciences · Torrance, California and 20 other locations · NCT07708727

• RNA-based vaccine BNT168 safety and immune response in adults with or without HIV

  A first-in-human study tests whether the RNA vaccine BNT168 is safe and can trigger immune responses in adults both with and without HIV.

  Recruiting at 3 sites Phase 1 BioNTech SE · Houston, Texas and 3 other locations · NCT07698600

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.